老年社区人群严重药物相互作用趋势及其与健康结局的纵向关联
基于爱尔兰老龄化纵向研究1-5波数据,纳入1917名≥65岁社区居住者,估计严重药物相互作用(DDI)患病率约26.2%至25.3%,倾向评分匹配后发现严重DDI暴露与急诊就诊、生活质量下降和功能衰退风险增加相关,其中增加出血风险的DDI关联最强。
要点
- 社区老年人群严重DDI患病率约四分之一,需持续关注。
- 严重DDI暴露与急诊就诊、生活质量下降和功能衰退风险增加相关。
- 增加出血风险的DDI与急诊就诊和功能衰退关联最强,应优先优化。
核心结论
- 严重DDI暴露与老年社区人群不良健康结局存在合理关联。
- 增加出血风险的DDI常见,应作为药物优化重点。
研究设计与样本
- 队列研究,使用爱尔兰老龄化纵向研究1-5波(每2年一波,2009年10月至2019年1月)的全国药房索赔数据与健康结局数据链接。
- 纳入≥65岁社区居住且每次索赔配发≥2种药物的居民,基线n=1917,平均年龄74.9(±6.2)岁,54.6%女性。
- 使用28 225条严重DDI列表估计DDI患病率,采用倾向评分匹配减少混杂,广义线性与Poisson回归建模关联。
主要发现
- 基线时45.4%为多重用药(5-9种常规药物),12.0%为严重多重用药(≥10种常规药物)。
- 共同配发的DDI患病率从第1波26.2%变化至第5波25.3%。
- 倾向评分匹配后,任何严重DDI暴露与第3波急诊就诊风险增加(aRR=1.49 [95%CI: 1.11, 2.00])和第4波急诊就诊风险增加(aRR=1.40 [1.02, 1.91])相关。
- 任何严重DDI暴露与第3波生活质量更差(β=-1.22 [-2.24, -0.20])和第2波功能衰退风险增加(RR=1.37 [1.08, 1.74])相关。
- 增加出血风险的DDI与第1波急诊就诊(aRR=1.95 [1.22, 3.10])、第3波急诊就诊(aRR=1.82 [1.02, 3.31])和第3波功能衰退(aRR=2.00 [1.05, 3.81])风险增加相关;禁忌DDI与第1波(β=-3.48 [-6.95, -0.01])和第5波(β=-8.50 [-11.00, -6.00])生活质量更差相关。
临床怎么用
- 对社区老年多重用药患者应常规筛查严重DDI,尤其关注增加出血风险的组合。
- 将增加出血风险的DDI作为药物优化和药学干预的优先靶点。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We estimate trends in severe drug-drug interaction (DDI) prevalence and examine longitudinal associations between DDI exposure and health outcomes (emergency department [ED] visits, quality-of-life [QoL] and functional decline) over approximately 10-years in the older community-dwelling population in Ireland. METHODS: This is a cohort study using linked national-pharmacy-claims data and health outcomes data from waves 1-5 (waves every 2-years; October 2009-January 2019) of The Irish LongituDinal study on Ageing. Community-dwellers aged ≥65 years dispensed ≥2 drugs per claim were eligible for inclusion. DDI prevalence was estimated using a list of 28 225 severe DDIs. Propensity score matching was used to minimize confounding. Generalized linear and Poisson regression was used to model the association between DDI exposure and health outcomes. DDI prevalence, adjusted relative risks (aRR), adjusted β-coefficients and 95% CIs are reported. RESULTS: At baseline, the mean age of n = 1917 eligible participants was 74.9(±6.2) years; 54.6% female, 45.4% polypharmacy (5-9 regular drugs), 12.0% major polypharmacy (≥10 regular drugs). Codispensed DDI prevalence varied from 26.2% (wave 1) to 25.3% (wave 5). After propensity score matching, any severe DDI exposure was associated with an increased risk of ED visit at wave 3 (aRR = 1.49 [95%CI: 1.11, 2.00]) and wave 4 (aRR = 1.40 [1.02, 1.91]); worse QoL at wave 3 (β = -1.22 [-2.24, -0.20]); and increased risk of functional decline at wave 2 (RR = 1.37 [1.08, 1.74]). Individuals with DDIs which increase bleeding risk had greatest risk of ED visit (wave 1: aRR = 1.95 [1.22, 3.10]; wave 3: aRR = 1.82 [1.02, 3.31]) and functional decline (wave 3: aRR = 2.00 [1.05, 3.81]). Those with a contraindicated DDI had worse QoL at wave 1 (β = -3.48 [-6.95, -0.01]) and wave 5 (β = -8.50[-11.00, -6.00]). CONCLUSIONS: We found plausible associations between severe DDI exposure and adverse health outcomes in the older community-dwelling population. DDIs which increase bleeding risk were common and should be targeted for medication optimization.
引用
- Hughes JE, Cahir C, Bennett KE, et al. Trends in drug-drug interaction prevalence and longitudinal associations with health outcomes in the older community-dwelling population: Findings from The Irish LongituDinal study on Ageing. Br J Clin Pharmacol. 2025. PMID: 40693557. doi:10.1002/bcp.70175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。